A more sensitive test for Lyme disease that may offer earlier detection and lower cost has been developed by scientists at the National Institutes of Health.
Lyme disease is a bacterial infection transmitted to animals and humans by deer ticks.
A skin lesion at the site of the bite is one of the first signs of infection followed by potential neurological, cardiac, and rheumatological complications upon entering the bloodstream.
The Centers for Disease Control and Prevention currently recommends a two-step blood test for diagnosing the disease, however, several limitations include low sensitivity during the early stages of infection, significant time and expense, and an inability to distinguish between active and prior infection.
In previous studies, the luciferase immunoprecipitation system (LIPS) test showed promise at detecting a variety of infectious agents including viral and fungal pathogens.
In the latest research, LIPS was evaluated for its ability to detect antibody responses to Borrelia burgdorferi proteins in blood samples taken from a patient group (some healthy and some with Lyme disease) as well as a control group.
The researchers found that diagnostic levels of 98 percent to 100 percent were achieved using LIPS in conjunction with the synthetic protein VOVO.
“These results suggest that screening by the LIPS test with VOVO and other B. burgdorferi antigens offers an efficient quantitative approach for evaluation of the antibody responses in patients with Lyme disease,” say the researchers.
The details are reported in the June 2010 issue of the journal Clinical and Vaccine Immunology.